Renal Dysfunction in Cirrhosis: Pathophysiology, Clinical Features and Therapy

Zakim and Boyer's Hepatology

Volumn , Issue , 2006, Pages 417-452

  Arroyo, Vicente ^a   Ginès, Pere ^a   Guevara, Mónica ^b   Rodés, Juan ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882862871     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3258-8.50027-9     Document Type: Chapter

References (259)

1. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002, 122:1658-1676.
2. Papper S. Hepatorenal syndrome. The Kidney in Liver Disease 1978, 91-112. Elsevier Biomedical, New York. M. Epstein (Ed.).
3. Shear L, Kleinerman J, Gabuzda GJ Renal failure in patients with cirrhosis of the liver. I. Clinical and pathologic characteristics. Am J Med 1965, 39:184-198.
4. Ellis AJ, O'Grady JG Clinical disorders or renal function in acute liver failure. Ascites and renal dysfunction in liver disease 1999, 63-78. Blackwell Science, Oxford. V. Arroyo, P. Gines, J. Rodes, R.W. Schrier (Eds.).
5. Stehman-Breen C, Johnson RJ Hepatitis C virus-associated glomerulonephritis. Adv Intern Med 1998, 43:79-97.
6. Post J, Sicam L. The clinical course of Laennec's cirrhosis under modern medical management. Med Clin North Am 1960, 44:639-651.
7. Pecikyan R, Kanzaki G, Berger EY Electrolyte excretion during the spontaneous recovery from the ascitic phase of cirrhosis of the liver. Am J Med 1967, 42:359-367.
8. Eisenmenger WJ, Blondheim SH, Bongiovanni AM, et al. Electrolyte studies on patients with cirrhosis of the liver. J Clin Invest 1950, 29:1491-1499.
9. Arroyo V, Rodes J. A rational approach to the treatment of ascites. Postgrad Med J 1975, 51:558-562.
10. Levy M, Allotey JB Temporal relationships between urinary salt retention and altered systemic hemodynamics in dogs with experimental cirrhosis. J Lab Clin Med 1978, 92:560-569.
11. Jimenez W, Martinez-Pardo A, Arroyo V, et al. Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology 1985, 5:245-250.
12. Gines P, Fernandez-Esparrach G, Arroyo V, et al. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997, 17:175-189.
13. Claria J, Jimenez W. Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. Ascites and renal dysfunction in liver disease 1999, 379-396. Blackwell Science, Oxford. V. Arroyo, P. Gines, J. Rodes, R.W. Schrier (Eds.).
14. Wilkinson SP, Jowett TP, Slater JD, et al. Renal sodium retention in cirrhosis: relation to aldosterone and nephron site. Clin Sci (Lond) 1979, 56:169-177.
15. Angeli P, Gatta A, Caregaro L, et al. Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur J Clin Invest 1990, 20:111-117.
16. Eggert RC Spironolactone diuresis in patients with cirrhosis and ascites. Br Med J 1970, 4:401-403.
17. Gatta A, Angeli P, Caregaro L, et al. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 1991, 14:231-236.
18. Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983, 84:961-968.
19. Jonassen TE, Heide AM, Janjua NR, et al. Collecting duct function in liver cirrhotic rats with early sodium retention. Acta Physiol Scand 2002, 175:237-244.
20. Jonassen TE, Christensen S, Sorensen AM, et al. Effects of chronic octreotide treatment on renal changes during cirrhosis in rats. Hepatology 1999, 29:1387-1395.
21. Jonassen TE, Petersen JS, Sorensen AM, et al. Aldosterone receptor blockade inhibits increased furosemide-sensitive sodium reabsorption in rats with liver cirrhosis. J Pharmacol Exp Ther 1998, 287:931-936.
22. Ring-Larsen H, Henriksen JH, Wilken C, et al. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J (Clin Res Ed) 1986, 292:1351-1353.
23. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000, 32:142-153.
24. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003, 38:258-266.
25. Strauss RM, Boyer TD Hepatic hydrothorax. Semin Liver Dis 1997, 17:227-232.
26. Xiol X, Guardiola J. Hepatic hydrothorax. Curr Opin Pulm Med 1998, 4:239-242.
27. Arroyo V, Bosch J, Gaya-Beltran J, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981, 94:198-201.
28. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988, 94:482-487.
29. Spahr L, Villeneuve JP, Tran HK, et al. Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. Hepatology 2001, 33:28-31.
30. Bernardi M, Di Marco C, Trevisani F, et al. Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 1993, 105:188-193.
31. Bernardi M, Di Marco C, Trevisani F, et al. The hemodynamic status of preascitic cirrhosis: an evaluation under steady-state conditions and after postural change. Hepatology 1992, 16:341-346.
32. Wong F, Liu P, Blendis L. Sodium homeostasis with chronic sodium loading in preascitic cirrhosis. Gut 2001, 49:847-851.
33. Wong F, Liu P, Allidina Y, et al. Pattern of sodium handling and its consequences in patients with preascitic cirrhosis. Gastroenterology 1995, 108:1820-1827.
34. Albillos A, Lledo JL, Rossi I, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995, 109:1257-1265.
35. Henriksen JH, Ring-Larsen H Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993, 18:688-695.
36. Wong F, Massie D, Hsu P, et al. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology 1993, 104:869-876.
37. Denison EK, Lieberman FL, Reynolds TB 9-Fluoro-hydrocortisone induced ascites in alcoholic liver disease. Gastroenterology 1971, 61:497-503.
38. La Villa G, Salmeron JM, Arroyo V, et al. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. Gastroenterology 1992, 102:2114-2119.
39. Wong F, Massie D, Hsu P, et al. Renal response to a saline load in well-compensated alcoholic cirrhosis. Hepatology 1994, 20:873-881.
40. Papper S, Saxon L. The diuretic response to administered water in patients with liver disease. II. Laennec's cirrhosis of the liver. AMA Arch Intern Med 1959, 103:750-757.
41. Shear L, Hall PW, Gabuzda GJ Renal failure in patients with cirrhosis of the liver. II. Factors influencing maximal urinary flow rate. Am J Med 1965, 39:199-209.
42. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001, 34:46-52.
43. Gines P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998, 28:851-864.
44. Gines P, Abraham WT, Schrier RW Vasopressin in pathophysiological states. Semin Nephrol 1994, 14:384-397.
45. Jimenez W, Gal CS, Ros J, et al. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther 2000, 295:83-90.
46. Bosch-Marce M, Poo JL, Jimenez W, et al. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J Pharmacol Exp Ther 1999, 289:194-201.
47. Fernandez-Varo G, Ros J, Cejudo-Martin P, et al. Effect of the V1a/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol 2003, 38:755-761.
48. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003, 124:933-939.
49. Guyader D, Patat A, Ellis-Grosse EJ, et al. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002, 36:1197-1205.
50. Verbalis JG Vasopressin V2 receptor antagonists. J Mol Endocrinol 2002, 29:1-9.
51. Schrier RW, Cadnapaphornchai MA, Umenishi F Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonists. Heart Dis 2001, 3:210-214.
52. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001, 138:18-21.
53. Inoue T, Ohnishi A, Matsuo A, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998, 63:561-570.
54. Rovira A, Cordoba J, Raguer N, et al. Magnetic resonance imaging measurement of brain edema in patients with liver disease: resolution after transplantation. Curr Opin Neurol 2002, 15:731-737.
55. Cordoba J, Alonso J, Rovira A, et al. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J Hepatol 2001, 35:598-604.
56. Restuccia T, Gomez-Anson B, Guevara M, et al. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 2004, 39:1613-1622.
57. Schroeder ET, Shear L, Sancetta SM, et al. Renal failure in patients with cirrhosis of the liver. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. Am J Med 1967, 43:887-896.
58. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956, 271:1121-1125.
59. Epstein M, Berk DP, Hollenberg NK, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970, 49:175-185.
60. Arroyo V, Bosch J, Mauri M, et al. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest 1979, 9:69-73.
61. Rimola A, Gines P, Arroyo V, et al. Urinary excretion of 6-keto-prostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome). J Hepatol 1986, 3:111-117.
62. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996, 23:164-176.
63. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105:229-236.
64. Platt JF, Marn CS, Baliga PK, et al. Renal dysfunction in hepatic disease: early identification with renal duplex Doppler US in patients who undergo liver transplantation. Radiology 1992, 183:801-806.
65. Bataller R, Gines P, Guevara M, et al. Hepatorenal syndrome. Semin Liver Dis 1997, 17:233-247.
66. Moore K. The hepatorenal syndrome. Clin Sci (Lond) 1997, 92:433-443.
67. Kew MC, Brunt PW, Varma RR, et al. Renal and intrarenal blood-flow in cirrhosis of the liver. Lancet 1971, 2:504-510.
68. Lancestremere RG, Davidson PL, Earley LE, et al. Renal failure in Laennec's cirrhosis. II. Simultaneous determination of cardiac output and renal hemodynamics. J Clin Invest 1962, 41:1922-1927.
69. Maroto A, Gines P, Arroyo V, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993, 17:788-793.
70. Iwatsuki S, Popovtzer MM, Corman JL, et al. Recovery from 'hepatorenal syndrome' after orthotopic liver transplantation. N Engl J Med 1973, 289:1155-1159.
71. Gonwa TA, Morris CA, Goldstein RM, et al. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991, 51:428-430.
72. Rimola A, Gavaler JS, Schade RR, et al. Effects of renal impairment on liver transplantation. Gastroenterology 1987, 93:148-156.
73. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989, 97:1304-1312.
74. Guevara M, Bru C, Gines P, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998, 28:39-44.
75. Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003, 38:1210-1218.
76. Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994, 20:1495-1501.
77. Navasa M, Follo A, Filella X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998, 27:1227-1232.
78. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.
79. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988, 94:1493-1502.
80. Gines P, Arroyo V, Rodes J. Ascites, hepatorenal syndrome, and spontaneous bacterial peritonitis. Evidence based gastroenterology and hepatology 1999, 427-442. BMJ Books, London. K.M. McDonald, A.K. Burroughs, B. Feagan (Eds.).
81. Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001, 34:671-676.
82. Boyer TD, Zia P, Reynolds TB Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979, 77:215-222.
83. Salerno F, Badalamenti S. Drug-induced renal failure in cirrhosis. Ascites and renal sysfunction in liver disease. Pathogenesis, diagnosis and treatment 1999, 511-521. Blackwell Science Malden, Philadelphia. V. Arroyo, P. Gines, J. Rodes, R.W. Schrier (Eds.).
84. Cabrera J, Arroyo V, Ballesta AM, et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982, 82:97-105.
85. McCormick PA, Greenslade L, Kibbler CC, et al. A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. Hepatology 1997, 25:833-836.
86. Bhathal PS, Grossman HJ Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985, 1:325-337.
87. Rockey DC Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001, 21:337-349.
88. Bataller R, Sancho-Bru P, Gines P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003, 125:117-125.
89. Gorbig MN, Gines P, Bataller R, et al. Human hepatic stellate cells secrete adrenomedullin: potential autocrine factor in the regulation of cell contractility. J Hepatol 2001, 34:222-229.
90. Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000, 118:1149-1156.
91. Morali GA, Sniderman KW, Deitel KM, et al. Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites?. J Hepatol 1992, 16:249-250.
92. Rector WG Portal hypertension: a permissive factor only in the development of ascites and variceal bleeding. Liver 1986, 6:221-226.
93. Ochs A, Rossle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995, 332:1192-1197.
94. Groszmann RJ Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994, 20:1359-1363.
95. Moller S, Henriksen JH The systemic circulation in cirrhosis. Ascites and renal dysfunction in liver disease 1999, 307-329. Blackwell Science, Oxford. V. Arroyo, P. Gines, J. Rodes, R.W. Schrier (Eds.).
96. Schrier RW, Niederberger M, Weigert A, et al. Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Semin Liver Dis 1994, 14:14-22.
97. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998, 27:35-41.
98. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000, 33:43-48.
99. Nicholls KM, Shapiro MD, Kluge R, et al. Sodium excretion in advanced cirrhosis: effect of expansion of central blood volume and suppression of plasma aldosterone. Hepatology 1986, 6:235-238.
100. Martin PY, Gines P, Schrier RW Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998, 339:533-541.
101. Wiest R, Groszmann RJ Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999, 19:411-426.
102. Morales-Ruiz M, Jimenez W, Perez-Sala D, et al. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology 1996, 24:1481-1486.
103. Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 1998, 101:235-242.
104. Such J, Frances R, Perez-Mateo M Nitric oxide in patients with cirrhosis and bacterial infections. Metab Brain Dis 2002, 17:303-309.
105. Epstein M, Levinson R, Sancho J, et al. Characterization of the renin-aldosterone system in decompensated cirrhosis. Circ Res 1977, 41:818-829.
106. Schroeder ET, Anderson GH, Goldman SH, et al. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int 1976, 9:511-519.
107. Pariente EA, Bataille C, Bercoff E, et al. Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 1985, 88:1255-1259.
108. Arroyo V, Bosch J, Mauri M, et al. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 1981, 11:221-229.
109. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998, 28:416-422.
110. Arroyo V, Planas R, Gaya J, et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 1983, 13:271-278.
111. Dudley F, Esler M. The sympathetic nervous system in cirrhosis. Ascites and renal dysfunction in liver disease 1999, 198-219. Blackwell Science, Oxford. V. Arroyo, P. Gines, J. Rodes, R.W. Schrier (Eds.).
112. DiBona GF, Sawin LL, Jones SY Characteristics of renal sympathetic nerve activity in sodium-retaining disorders. Am J Physiol 1996, 271:R295-R302.
113. Uriz J, Gines P, Ortega R, et al. Increased plasma levels of neuropeptide Y in hepatorenal syndrome. J Hepatol 2002, 36:349-355.
114. Liu H, Song D, Lee SS Cirrhotic cardiomyopathy. Gastroenterol Clin Biol 2002, 26:842-847.
115. Ma Z, Lee SS Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996, 24:451-459.
116. Cardenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab 2003, 17:607-622.
117. Cahill PA, Redmond EM, Sitzmann JV Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001, 89:273-293.
118. Epstein M, Goligorsky MS Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. J Nephrol 1997, 10:120-135.
119. Jimenez W, Poo JL, Leivas A Endothelin and systemic, renal and hepatic hemodynamics disturbances in cirrhosis. Ascites and renal dysfunction in liver disease 1999, 291-303. Blackwell Science, Oxford. V. Arroyo, P. Gines, J. Rodes, R.W. Schrier (Eds.).
120. Soper CP, Latif AB, Bending MR Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996, 347:1842-1843.
121. Huber M, Kastner S, Scholmerich J, et al. Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome. Eur J Clin Invest 1989, 19:53-60.
122. Zipser RD, Radvan GH, Kronborg IJ, et al. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983, 84:697-703.
123. Zipser RD, Kronborg I, Rector W, et al. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. Gastroenterology 1984, 87:1228-1232.
124. Sacerdoti D, Balazy M, Angeli P, et al. Eicosanoid excretion in hepatic cirrhosis Predominance of 20-HETE. J Clin Invest 1997, 100:1264-1270.
125. Stanley AJ, Forrest EH, Dabos K, et al. Natriuretic effect of an adenosine-1 receptor antagonist in cirrhotic patients with ascites. Gastroenterology 1998, 115:406-411.
126. Llach J, Gines P, Arroyo V, et al. Effect of dipyridamole on kidney function in cirrhosis. Hepatology 1993, 17:59-64.
127. Moore K. Arachidonic acid metabolites and the kidney in cirrhosis. Ascites and renal dysfunction in liver disease 1999, 249-272. Blackwell Science, Oxford. V. Arroyo, P. Gines, J. Rodes, R.W. Schrier (Eds.).
128. Claria J, Kent JD, Lopez-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005, 41:579-587.
129. Laffi G, La Villa G, Pinzani M, et al. Arachidonic acid derivatives and renal function in liver cirrhosis. Semin Nephrol 1997, 17:530-548.
130. Gines P, Jimenez W, Arroyo V, et al. Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology 1988, 8:636-642.
131. Levy M. Atrial natriuretic peptide: renal effects in cirrhosis of the liver. Semin Nephrol 1997, 17:520-529.
132. La Villa G, Laffi G, Gentilini P. Atrial natriuretic peptide and other natriuretic factors in cirrhosis. Ascites and renal dysfunction in liver disease 1999, 231-248. Blackwell Science, Oxford. V. Arroyo, P. Gines, J. Rodes, R.W. Schrier (Eds.).
133. Gulberg V, Moller S, Henriksen JH, et al. Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut 2000, 47:852-857.
134. Salo J, Jimenez W, Kuhn M, et al. Urinary excretion of urodilatin in patients with cirrhosis. Hepatology 1996, 24:1428-1432.
135. Henriksen JH, Gotze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003, 52:1511-1517.
136. Ros J, Clariz J, Jimenez W, et al. Role of nitric oxide and prost cyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995, 22:915-920.
137. Criado M, Flores O, Ortiz MC, et al. Elevated glomerular and blood mononuclear lymphocyte nitric oxide production in rats with chronic bile duct ligation: role of inducible nitric oxide synthase activation. Hepatology 1997, 26:268-276.
138. Bosch-Marce M, Morales-Ruiz M, Jimenez W, et al. Increased renal expression of nitric oxide synthase type III in cirrhotic rats with ascites. Hepatology 1998, 27:1191-1199.
139. Hattori K, Hasumura Y, Takeuchi J. Role of renal kallikrein in the derangement of sodium and water excretion in cirrhotic patients. Scand J Gastroenterol 1984, 19:844-848.
140. Perez-Ayuso RM, Arroyo V, Camps J, et al. Renal kallikrein excretion in cirrhotics with ascites: relationship to renal hemodynamics. Hepatology 1984, 4:247-252.
141. Robertson GL, Berl T Pathophysiology of water metabolism: water retaining disorders. The kidney 1996, 873-928. WB Saunders, Philadelphia. 5th edn. B.M. Brenner, F.C. Recotr (Eds.).
142. Arroyo V, Rodes J, Gutierrez-Lizarraga MA, et al. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976, 21:249-256.
143. Papper S, Rosenbaum JD Abnormalities in the excretion of water and sodium in 'compensated' cirrhosis of the liver. J Lab Clin Med 1952, 40:523-530.
144. Caregaro L, Lauro S, Angeli P, et al. Renal water and sodium handling in compensated liver cirrhosis: mechanism of the impaired natriuresis after saline loading. Eur J Clin Invest 1985, 15:360-364.
145. Trevisani F, Bernardi M, Gasbarrini A, et al. Bed-rest-induced hypernatriuresis in cirrhotic patients without ascites: does it contribute to maintain 'compensation?. J Hepatol 1992, 16:190-196.
146. Bernardi M, Trevisani F, Santini C, et al. Aldosterone related blood volume expansion in cirrhosis before and during the early phase of ascites formation. Gut 1983, 24:761-766.
147. Merkel C, Gatta A, Donada C, et al. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale. Hepatology 1995, 22:808-813.
148. Salmeron JM, Ruiz dA, Gines A, et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 1993, 17:800-806.
149. Gines P, Arrovo V, Rodes J. Pharmacotherapy of ascites associated with cirrhosis. Drugs 1992, 43:316-332.
150. Gerbes AL Medical treatment of ascites in cirrhosis. J Hepatol 1993, 17(Suppl 2):S4-S9.
151. Henriksen JH, Ring-Larsen H, Kanstrup IL, et al. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis. Gut 1984, 25:1034-1043.
152. Ring-Larsen H, Hesse B, Henriksen JH, et al. Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release. Hepatology 1982, 2:304-310.
153. Fernandez-Rodriguez C, Prieto J, Quiroga J, et al. Atrial natriuretic factor in cirrhosis: relationship to renal function and hemodynamic changes. J Hepatol 1994, 21:211-216.
154. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000, 32(Suppl 1):157-170.
155. Kostreva DR, Castaner A, Kampine JP Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol 1980, 238:R390-R394.
156. Arroyo V, Bosch J, Mauri M, et al. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest 1979, 9:69-73.
157. Bichet DG, Van Putten VJ, Schrier RW Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982, 307:1552-1557.
158. Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980, 78:92-99.
159. 2O transport in Henle's loop of the rat. Am J Physiol 1982, 243:F576-F580.
160. DiBona GF, Kopp UC Neural control of renal function. Physiol Rev 1997, 77:75-197.
161. Gonzalez-Abraldes J, Albillos A, Banares R, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001, 121:382-388.
162. Albillos A, Banares R, Barrios C, et al. Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. Gastroenterology 1992, 102:248-254.
163. Claria J, Jimenez W, Arroyo V, et al. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991, 100:494-501.
164. Planas R, Arroyo V, Rimola A, et al. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983, 84:247-252.
165. Arroyo V, Gines P, Rimola A, et al. Renal function abnormalities, prostaglandins, and effects of nonsteroidal antiinflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 1986, 81:104-122.
166. Arroyo V, Rimola A, Gaya J, et al. Prostaglandins and renal function in cirrhosis. Prog Liver Dis 1986, 8:505-523.
167. Quintero E, Gines P, Arroyo V, et al. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 1986, 42:298-303.
168. Ros J, Claria J, Jimenez W, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995, 22:915-920.
169. Zhang PL, Jimenez W, Mackenzie HS, et al. HS-142-1, a potent antagonist of natriuretic peptides in vitro and in vivo. J Am Soc Nephrol 1994, 5:1099-1105.
170. Angeli P, Jimenez W, Arroyo V, et al. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994, 20:948-954.
171. Bichet D, Szatalowicz V, Chaimovitz C, et al. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982, 96:413-417.
172. Perez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984, 26:72-80.
173. Maroto A, Gines A, Salo J, et al. Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: prognostic value of resistive index. Hepatology 1994, 20:839-844.
174. Sato S, Ohnishi K, Sugita S, et al. Splenic artery and superior mesenteric artery blood flow: nonsurgical Doppler US measurement in healthy subjects and patients with chronic liver disease. Radiology 1987, 164:347-352.
175. Diez J, Simon MA, Anton F, et al. Tubular sodium handling in cirrhotic patients with ascites as analysed by the renal lithium clearance method. Eur J Clin Invest 1990, 20:266-271.
176. Arroyo V, Bernardi M, Epstein M, et al. Pathophysiology of ascites and functional renal failure in cirrhosis. J Hepatol 1988, 6:239-257.
177. Llovet JM, Planas R, Morillas R, et al. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol 1993, 88:388-392.
178. Llovet JM, Rodriguez-Iglesias P, Moitinho E, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination. A retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997, 26:88-95.
179. Fernandez J, Navasa M, Ruiz-del-Arbol L, et al. Effects of spontaneous bacterial peritonitis (SBP) on systemic haemodynamics in patients with cirrhosis. J Hepatol 2001, 34:73.
180. Gonzalez-Garcia M, Monescillo A, Peña E, et al. Estudio prospectivo clínico-hemodinámico del síndrome hepatorenal (SHR) en la cirrosis hepática [abstr]. Rev Esp Enf Dig 2001, 93(Suppl 1):11.
181. Claria J, Jimenez W, Ros J, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 1992, 15:343-349.
182. Bailie MD, Rector FC, Seldin DW Angiotensin II in arterial and renal venous plasma and renal lymph in the dog. J Clin Invest 1971, 50:119-126.
183. Osswald H, Vallon V, Muhlbauer B. Role of adenosine in tubuloglomerular feedback and acute renal failure. J Autonom Pharmacol 1996, 16:377-380.
184. Lopez-Parra M, Claria J, Planaguma A, et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002, 135:891-900.
185. Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002, 36:374-380.
186. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8:1151-1157.
187. Colombato LA, Albillos A, Groszmann RJ Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 1992, 15:323-328.
188. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999, 29:1690-1697.
189. Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002, 36:941-948.
190. Moller S, Henriksen JH Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001, 36:785-794.
191. Salo J, Gines A, Anibarro L, et al. Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. Hepatology 1995, 22:479-487.
192. Salo J, Guevara M, Fernandez-Esparrach G, et al. Impairment of renal function during moderate physical exercise in cirrhotic patients with ascites: relationship with the activity of neurohormonal systems. Hepatology 1997, 25:1338-1342.
193. Ring-Larsen H, Henriksen JH, Wilken C, et al. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J (Clin Res Ed) 1986, 292:1351-1353.
194. Reynolds TB, Lieberman FL, Goodman AR Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. Gut 1978, 19:549-553.
195. Arroyo V, Gines P, Rodes J. Treatment of ascites in patients with cirrhosis of the liver. J Hepatol 1986, 2:504-512.
196. Gauthier A, Levy VG, Quinton A, et al. Salt or no salt in the treatment of cirrhotic ascites: a randomised study. Gut 1986, 27:705-709.
197. Garcia-Tsao G Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001, 120:726-748.
198. Suki WN, Eknoyan G Physiology of diuretic action. The kidney: physiology and pathophysiology 1992, 3629-3670. Raven Press, New York. 2nd edn. D.W. Seldin, G. Giebisch (Eds.).
199. Puschet JB, Winaver J Effects of diurectics on renal function. Handbook of physiology 1992, 2335-2407. Oxford University Press, Oxford. E. Ewindhager (Ed.).
200. Attallah AA Interaction of prostaglandins with diuretics. Prostaglandins 1979, 18:369-375.
201. Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 1992, 102:1680-1685.
202. Karim A. Spironolactone metabolism in man revisited. Contemporary trends in diuretic therapy 1986, 23-27. Excerpta Medica, Amsterdam. H.R. Brunner (Ed.).
203. Verrey F. Regulation of gene expression by aldosterone in tight epithelia. Semin Nephrol 1990, 10:410-420.
204. Marver D, Stewart J, Funder JW, et al. Renal aldosterone receptors: studies with (3H)aldosterone and the anti-mineralocorticoid (3H)spirolactone (SC-26304). Proc Natl Acad Sci USA 1974, 71:1431-1435.
205. Cheng SC, Suzuki K, Sadee W, et al. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta-and 18-hydroxylation in bovine and human adrenal cortical mitochondria. Endocrinology 1976, 99:1097-1106.
206. Corvol P, Claire M, Oblin ME, et al. Mechanism of the antimineralocorticoid effects of spirolactones. Kidney Int 1981, 20:1-6.
207. Arroyo V, Bosch J, Casamitjana R, et al. Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level. Gut 1980, 21:855-859.
208. Campra JL, Reynolds TB Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. Am J Dig Dis 1978, 23:1025-1030.
209. Lopez-Novoa JM, Rengel MA A micropuncture study of salt and water retention in chronic experimental cirrhosis. Am J Physiol 1977, 232:F315-F318.
210. Chiandussi L, Bartoli E, Arras S. Reabsorption of sodium in the proximal renal tubule in cirrhosis of the liver. Gut 1978, 19:497-503.
211. Takaya A, Fukui H, Matsumura M, et al. Stepped care medical treatment for cirrhotic ascites: analysis of factors influencing the response to treatment. J Gastroenterol Hepatol 1995, 10:30-35.
212. Forns X, Gines A, Gines P, et al. Management of ascites and renal failure in cirrhosis. Semin Liver Dis 1994, 14:82-96.
213. Shear L, Ching S, Gabuzda GJ Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 1970, 282:1391-1396.
214. Sherlock S, Senewiratne B, Scott A, et al. Complications of diuretic therapy in hepatic cirrhosis. Lancet 1966, 1:1049-1052.
215. Rodes J, Bosch J, Arroyo V. Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Med J 1975, 51:492-497.
216. Baertl JM, Sancetta SM, Gabuzda GJ Relation of acute potassium depletion to renal ammonium metabolism in patients with cirrhosis. J Clin Pharmacol 1963, 42:696-707.
217. Gussin RZ Potassium-sparing diuretics. J Clin Pharmacol 1977, 17:651-662.
218. Good DW, Wright FS Luminal influences on potassium secretion: sodium concentration and fluid flow rate. Am J Physiol 1979, 236:F192-F205.
219. Stripp B, Taylor AA, Bartter FC, et al. Effect of spironolactone on sex hormones in man. J Clin Endocrinol Metab 1975, 41:777-781.
220. Menard RH, Loriaux DL, Bartter FC, et al. The effect of the administration of spironolactone on the concentration of plasma testosterone, estradiol and cortisol in male dogs (1). Steroids 1978, 31:771-782.
221. Angeli P, Albino G, Carraro P, et al. Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 1996, 23:264-273.
222. Lee FY, Lee SD, Tsai YT, et al. A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps. J Hepatol 1991, 12:236-240.
223. Nielsen S, Marples D, Frokiaer J, et al. The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2. Kidney Int 1996, 49:1718-1723.
224. Lolait SJ, O'Carroll AM, McBride OW, et al. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992, 357:336-339.
225. Fushimi K, Uchida S, Hara Y, et al. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993, 361:549-552.
226. Knepper MA, Nielsen S, Chou CL, et al. Mechanism of vasopressin action in the renal collecting duct. Semin Nephrol 1994, 14:302-321.
227. Knepper MA Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol 1997, 272:F3-F12.
228. Hofbauer KG, Studer W, Mah SC, et al. The significance of vasopressin as a pressor agent. J Cardiovasc Pharmacol 1984, 6(Suppl 2):S429-S438.
229. Arroyo V, Claria J, Salo J, et al. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994, 14:44-58.
230. Leander JD Further study of kappa opioids on increased urination. J Pharmacol Exp Ther 1983, 227:35-41.
231. Leander JD, Zimmerman DM Effects of picenadol and its agonist and antagonist isomers on schedule-controlled behavior. J Pharmacol Exp Ther 1983, 227:671-675.
232. Peters GR, Ward NJ, Antal EG, et al. Diuretic actions in man of a selective kappa opioid agonist: U-62,066E. J Pharmacol Exp Ther 1987, 240:128-131.
233. Ohnishi A, Mihara M, Yasuda S, et al. Aquaretic effect of the stable dynorphin-A analog E2078 in the human. J Pharmacol Exp Ther 1994, 270:342-347.
234. Kinter LB, Huffman WF, Stassen FL Antagonists of the antidiuretic activity of vasopressin. Am J Physiol 1988, 254:F165-F177.
235. Laszlo FA, Laszlo F, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol Rev 1991, 43:73-108.
236. Perez-Ayuso RM, Arroyo V, Camps J, et al. Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics. Nephron 1984, 36:30-37.
237. Gadano A, Moreau R, Pessione F, et al. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 2000, 32:38-42.
238. Sawyer WH, Manning M The development of potent and specific vasopressin antagonists. Kidney Int Suppl 1988, 26:S34-S37.
239. Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science 1991, 252:572-574.
240. Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992, 105:787-791.
241. Albright JD, Reich MF, Delos Santos EG, et al. 5-Fluoro-2-methyl- N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem 1998, 41:2442-2444.
242. Chan PS, Coupet J, Park HC, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998, 449:439-443. 439-443.
243. Serradeil-Le Gal C, Lacour C, Valette G, et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996, 98:2729-2738.
244. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998, 287:860-867.
245. Tahara A, Saito M, Sugimoto T, et al. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1998, 357:63-69.
246. Tsuboi Y, Ishikawa S, Fujisawa G, et al. Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats. Kidney Int 1994, 46:237-244.
247. Ohnishi A, Orita Y, Okahara R, et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993, 92:2653-2659.
248. Ohnishi A, Orita Y, Takagi N, et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 1995, 272:546-551.
249. Gines P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet 2003, 362:1819-1827.
250. Gulberg V, Bilzer M, Gerbes AL Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999, 30:870-875.
251. Mulkay JP, Louis H, Donckier V, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001, 64:15-19.
252. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002, 122:923-930.
253. Alessandria C, Venon WD, Marzano A, et al. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002, 14:1363-1368.
254. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000, 47:288-295.
255. Alam L, Bass NM, La Berge JM, et al. Treatment of hepatorenal syndrome with the transjugular intrahepatic shunt (TIPS). Gastroenterology 1995, 108:1024A.
256. Ochs A, Rösle M, Haag K, et al. TIPS for hepatorenal syndrome. Hepatology 1994, 20:114A.
257. Brensing KA PJST TIPS in hepatorenal syndrome. Treatment of liver diseases 1999, 53-59. Masson, Barcelona. V. Arroyo (Ed.).
258. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004, 40:55-64.
259. Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648.